[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Eikon Therapeutics\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":167},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,73,98,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100535538","phase-1-a-first-in-human-study-of-parp1-selective-inhibitor-imp1734-in-participants-with-advanced-solid-tumors-100535538",false,"NCT06253130","A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","A First-in-human, Phase 1\u002F2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors","Key Inclusion Criteria\n\n* Breast cancer; must have received at least one prior chemotherapy in neoadjuvant\u002Fadjuvant\u002Fmetastatic setting, must have received hormonal therapy if HR+,\n* HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease\n* mCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy\n* Age ≥ 18 years at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n* Adequate organ function\n* Life expectancy ≥ 12 weeks\n* Should have evaluable disease as defined by RECIST1.1 and\u002For CA125 or PSA\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of IMP1734\n* deleterious or suspected deleterious germline or somatic mutations of select HRR genes\n* up to 1 prior line of PARP inhibitor containing treatment\n\nKey Exclusion Criteria:\n\n* Any investigational or approved anti-cancer therapies administered within 28 days\u002F before the first dose of IMP1734\n* Have received prior PARP1 selective inhibitors\n* Mean resting QTcF \\> 470 ms or QTcF \\\u003C 340 ms\n* Active or untreated central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Infections\n\n  \\- An active hepatitis B\u002FC infection\n* Any known predisposition to bleeding\n* Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability","ALL","18 Years","89 Years",{"count":20,"type":21},156,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This study investigates the safety and tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of EIK1003 in participants with advanced solid tumors.",[28],"Advanced Solid Tumor",[30,31,32],"EIK1003","EIK1003-001","IMP1734","RECRUITING","2026-06-11",{"date":36,"type":37},"2026-06-15","ACTUAL",{"date":39,"type":37},"2023-12-11",{"date":41,"type":21},"2027-12-01",{"name":43,"class":44},"Eikon Therapeutics","INDUSTRY",57,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100621030","phase-2-a-safety-and-efficacy-study-of-eik1001-in-combination-with-pembrolizumab-and-chemotherapy-in-participants-with-stage-4-non-small-cell-lung-cancer-100621030","NCT07365319","A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.","A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2\u002F3 Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).","TeLuRide-008","Key Inclusion Criteria:\n\n1. Participant must be ≥ 18 years old at the time of signing the informed consent.\n2. Participant has a life expectancy of at least 3 months.\n3. Participant has histologically or cytologically confirmed Stage 4 NSCLC predominately squamous or non-squamous) and is considered a candidate for standard therapy with pembrolizumab and chemotherapy. Participants with NSCLC-NOS (not otherwise specified) will be considered as non-squamous NSCLC.\n4. Participant must have documented evidence that mutation-directed therapy is not indicated, based on the absence of tumor-activating mutations or fusions (e.g., but not limited to EGFR, ALK, RET, ROS1, BRAF) for which approved first-line targeted therapies are available to the participant in their respective country.\n5. Participant has at least 1 lesion with measurable disease at Baseline according to RECIST 1.1 as determined locally. Lesions situated in a previously irradiated area are considered measurable if progression has been shown in such lesions.\n6. Participant has not received prior systemic therapy for advanced\u002Fmetastatic NSCLC.\n\n   Note: Participants who received adjuvant or neoadjuvant treatment (after surgery and\u002For radiation therapy) and developed recurrent or metastatic disease more than 1 year after completing therapy are eligible.\n7. Participant has an ECOG Performance Status of 0 to 1 assessed no more than 10 days before start of the treatment.\n8. Participant has tumor tissue available for PD-L1 testing from a site that was not radiated prior to biopsy, and was obtained, ideally, after diagnosis of metastatic disease. Biopsies obtained prior to receipt of adjuvant\u002Fneoadjuvant chemotherapy will be permitted if recent biopsy is not feasible (provided the specimen is \\\u003C 3yrs old).\n\nKey Exclusion Criteria:\n\n1. has small cell elements present histologically and\u002For the tumors are not predominantly non-squamous or squamous NSCLC.\n2. is currently actively enrolled in or has recently participated in a study of an investigational agent and received investigational therapy within 4 weeks or 5 half-lives (whichever is longer) of administration of EIK1001 or placebo.\n3. has had major surgery (\\\u003C 3 weeks prior to the first dose of study intervention administration).\n4. has received a live-virus vaccination within 30 days of the start of study intervention initiation.\n5. has received radiation therapy within 7 days of the first dose of study intervention administration.\n6. has completed palliative radiotherapy within 7 days of the first dose of study intervention administration.",{"count":55,"type":21},750,[25,57],"PHASE3","This is a study to evaluate the safety and efficacy of EIK1001 administered intravenously in combination with pembrolizumab and histologically appropriate chemotherapy for patients with stage 4 NSCLC.",[60,61],"Non Small Cell Lung Cancer (Squamous or Non Squamous)","Stage 4 NSCLC",[63,64],"Non Small Cell Lung Cancer","EIK1001","2026-05-18",{"date":67,"type":37},"2026-05-20",{"date":65,"type":21},{"date":70,"type":21},"2040-12-31",{"name":43,"class":44},3,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},"100569673","phase-2-safety-and-efficacy-of-eik1001-in-combo-with-pembro-versus-placebo-and-pembro-as-first-line-therapy-in-patients-with-advanced-melanoma-100569673","NCT06697301","Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.","A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2\u002F3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants With Advanced Melanoma (TeLuRide-006)","Inclusion Criteria:\n\nTo be eligible for inclusion in this study, participants must:\n\n* Be ≥ 18 years of age on the day of signing of informed consent.\n* Have a life expectancy of at least 3 months.\n* Have histologically or cytologically confirmed Stage 3 (unresectable) or Stage 4 metastatic melanoma per AJCC 8th ed. and be eligible for standard therapy with pembrolizumab.\n* Have at least 1 lesion with measurable disease at Baseline by CT or MRI according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by assessment of local site Investigator\u002Fradiologist.\n* Have known BRAF V600 mutation status or consent to BRAF V600 mutation testing per local institutional standards during the screening period\n* Have completed prior radiotherapy at least 2 weeks prior to study treatment administration.\n* Have an ECOG Performance Status of 0 to 1.\n* Have adequate organ and marrow function as defined by normal CBC, coagulation, serum chemistry and liver function tests on specimens collected within 10 days of treatment start.\n* Have a negative serum pregnancy test within 72 hours prior to receiving the first dose of study medication (applies to women of childbearing potential \\[WOCBP\\]).\n* Be willing to use either 2 adequate methods of contraception, 1 adequate method plus a hormonal method of contraception, or be willing to abstain from heterosexual activity throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to WOCBP who are not menopausal for \\> 2 years, post-hysterectomy\u002Foophorectomy, or surgically sterilized).\n* Agree to use an approved adequate contraceptive method throughout the study (Visit 1 to 120 days after the last dose of study therapy; applies to sexually active male participants with a partner who is WOCBP).\n* Be willing and able to provide written, informed consent for the study.\n\nExclusion Criteria:\n\nA participant is excluded from the study if any of the following criteria apply:\n\n* Has melanoma of ocular origin.\n* Is currently enrolled in or has recently participated in a study of an IMP and received an IMP within 4 weeks or 5 half-lives (whichever is shorter) of administration of EIK1001 or placebo.\n* Prior to the 1St dose of EIK1001 or placebo, the prospective participant has received systemic therapy for advanced melanoma.\n* Note: prior adjuvant or neoadjuvant melanoma therapies (such as anti-PD-1 or anti CTLA 4 therapies or BRAF\u002FMEK inhibitors) are permitted if all related AEs have either returned to Baseline or stabilized, with a minimum of 6 months between the last dose of prior therapy and documented disease progression.\n* Experienced a ≥ Grade 3 AE while receiving prior anti PD 1 therapy.\n* Has had major surgery (\\\u003C 3 weeks prior to the first dose).\n* Has received a live-virus vaccination within 30 days of the first dose of study treatment.\n* Has a known history of prior malignancy, unless the participant has undergone potentially curative therapy with no evidence of disease recurrence for 5 years.\n* Has known active CNS metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate if they are clinically stable for at least 4 weeks with no evidence of new or enlarging brain metastases. There must be no need for immunosuppressive doses of glucocorticoids for at least 2 weeks prior to study treatment administration.\n* There is a mean resting QTcF \\> 470 ms on triplicate electrocardiograms.\n* There is active autoimmune disease that has required systemic treatment in the past 2 years. The following autoimmune conditions are permitted: Type 1 diabetes, hypothyroidism (on hormone replacement), or- vitiligo, psoriasis and alopecia as long as no systemic treatment is required.\n* There is either chronic treatment with systemic steroids, other immunosuppressive medication, or either of these has been administered within 14 days of start of study treatment.\n* Note: Participants with asthma that require intermittent use of bronchodilators, inhaled steroids, or local steroid injections are eligible. Steroid replacement for adrenal insufficiency is also permitted.\n* There is a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002F interstitial lung disease.\n* There are any active infections requiring therapy.\n* There is uncontrolled human immunodeficiency virus (HIV) infection. HIV-infected participants with well-controlled HIV may enroll.\n* There is a positive test result for hepatitis B virus (HBV) or HCV indicating presence of virus (it is expected that all participants will have been serologically tested for hepatitis B in advance of this study, with HBsAG, anti-HBc IgG, and anti-HBs as per ASCO 2020 Provisional Clinical Opinion \\[PCO\\] on universal Serologic testing for hepatitis B at the onset of anticancer therapy; screening should also include an anti-HCV test prior to start of cancer treatment:\n* There is a history or clinical evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study or interfere with the participant's participation for the full duration of the study\n* Known psychiatric or substance abuse disorder that would interfere with cooperation with study requirements.\n* There is a known history of regular illicit drug use and\u002For recent history (within the last year) of substance abuse (including alcohol).\n* Participant is pregnant, breastfeeding, or planning to conceive or father children within the projected duration of the study.\n* Participant is currently receiving medications known to be strong inhibitors or inducers of CYP3A4 and CYP1A2.",{"count":81,"type":21},740,[25,57],"The study is for patients with advanced melanoma who are eligible for standard therapy with Pembrolizumab.",[85],"Advanced Melanoma",[87,88],"Metastatic","Advanced","2026-05-06",{"date":91,"type":37},"2026-05-08",{"date":93,"type":37},"2025-05-22",{"date":95,"type":21},"2040-12",{"name":43,"class":44},107,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":22,"phases":107,"briefSummary":108,"conditions":109,"keywords":117,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100613133","phase-1-eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including-microsatellite-instability-high-msi-h-tumors-100613133","NCT07262619","EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors","A Multicenter, Multi-Part, Phase 1\u002F2 Study of EIK1005 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors, Including Checkpoint Inhibitor Naïve Participants With Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors","Key Inclusion Criteria:\n\n1. is ≥ 18 years of age at the time of signing the informed consent.\n2. has a life expectancy of at least 3 months.\n3. has histologically or cytologically documented advanced (unresectable and\u002For metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.\n4. In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.\n5. has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.\n6. has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.\n7. has an adequate organ and marrow function.\n\nKey Exclusion Criteria:\n\n1. has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).\n2. has received prior treatment with Werner (WRN) inhibitor.\n3. has a history of relevant drug hypersensitivity, ascertained or presumptive allergy\u002Fhypersensitivity to the active drug substance and\u002For formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.\n4. In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n5. has known additional malignancy that is progressing or has required active treatment within the past 3 years.\n6. has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.\n7. has mean resting QTcF \\> 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).\n8. has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).\n9. has history of (non-infectious) pneumonitis\u002Fpneumonitis\u002Finterstitial lung disease that required steroids or current pneumonitis\u002Finterstitial lung disease.\n10. has active tuberculosis.\n11. has any active infections requiring systemic therapy.",{"count":106,"type":21},160,[24,25],"The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.",[110,111,112,113,114,115,116],"Advanced Solid Tumors","MSI-H or dMMR Advanced Solid Tumors","MSI-H\u002FdMMR Gastric Cancer","MSI-H\u002FdMMR Colorectal Cancer","MSI-H\u002FdMMR Gastroesophageal-junction Cancer","Endometrial Cancer","Mismatch Repair Deficient or MSI-High Solid Tumors",[118,119,120,121,122,123,110,87,124,125,126,127,128],"Werner helicase","WRN","MSI-H","dMMR","DNA mismatch repair","EIK1005","MSI-H\u002FdMMR Endometrial Cancer","MSI-H\u002FdMMR Prostate Cancer","Pembrolizumab","Mismatch Repair Deficient (dMMR)","Microsatellite Instability High (MSI-H)","2026-04-06",{"date":131,"type":37},"2026-04-08",{"date":133,"type":37},"2026-01-20",{"date":135,"type":21},"2029-03",{"name":43,"class":44},10,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":143,"acronym":144,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":151,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":137},"100585797","phase-1-a-study-of-parp1-selective-inhibitor-eik1004-imp1707-in-participants-with-advanced-solid-tumors-100585797","NCT06907043","A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.","A Phase 1\u002F2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors","EIK1004-001","• Breast cancer: must have received at least one prior chemotherapy in neoadjuvant\u002Fadjuvant\u002Fmetastatic setting, must have received hormonal therapy if HR+, HGSOC or high grade endometrioid EOC, fallopian tube or primary peritoneal cancer; must have received at least one prior platinum-based chemotherapy for advanced disease.\n\nmCRPC with ongoing ADT, must have received NHA and up to 1 prior line of taxane chemotherapy; Pancreatic cancer, must have prior 1L therapy\n\n* Age ≥ 18 years at the time of informed consent\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤1\n* Adequate organ function\n* Life expectancy ≥ 12 weeks\n* Should have evaluable disease as defined by RECIST1.1 and\u002For CA125 or PSA\n* Female subjects of childbearing potential and male subjects must agree to use an effective method of contraception from study entry up to 6 months after the last dose of EIK1004 (IMP1707)\n* Deleterious or suspected deleterious germline or somatic mutations of select HRR genes\n* Up to 1 prior line of PARP inhibitor containing treatment\n\nCNS Inclusion Criteria:\n\n* Untreated CNS metastases (measurable and\u002For non-measurable) not needing immediate local therapy.\n* Previously treated CNS metastases\n\nKey Exclusion Criteria:\n\n* Any investigational or approved anti-cancer therapies administered within 28 days\u002F before the first dose of EIK1004 (IMP1707)\n* Have received prior PARP1 selective inhibitors\n* Mean resting QTcF \\> 470 ms or QTcF \\\u003C 340 ms\n* Infections\n\n  \\- An active hepatitis B\u002FC infection\n* Any known predisposition to bleeding\n* Unable to swallow oral medications OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition that might impair the bioavailability\n\nCNS Exclusion Criteria\n\n* Any untreated brain lesions \\> 2.0 cm in size.\n* Ongoing use of systemic corticosteroids for control of symptoms of CNS metastases \\\u003C 7 days prior to the first dose of study treatment or requirement for \\> 10 mg prednisone\u002Fday.\n* Any brain lesion requiring immediate local therapy, including (but not limited to) a lesion in an anatomic site where an increase in size or possible treatment-related edema may pose risk to the participant (eg, brain stem lesions).\n* Known, symptomatic leptomeningeal disease.\n* Have poorly controlled seizures.",{"count":147,"type":21},130,[24,25],"This study will evaluate the safety, tolerability, and preliminary efficacy of EIK1004 (IMP1707) in participants with recurrent advanced\u002Fmetastatic breast cancer, ovarian cancer, metastatic castrate resistant prostate cancer (mCRPC) and pancreatic cancer with deleterious\u002Fsuspected deleterious mutations of select homologous recombination repair (HRR) genes.\n\nCondition or disease Intervention\u002Ftreatment Phase Advanced Solid Tumors Drug: EIK1004 (IMP1707) Phase 1\u002FPhase 2",[110],[152,153,154,155,156,157,158],"EIK1004","IMP1707","Advanced\u002Frecurrent\u002Fmetastatic pancreatic adenocarcinoma","Brain metastases","Advanced HER2-negative breast adenocarcinoma","Recurrent HER2-negative breast adenocarcinoma","metastatic HER2-negative breast adenocarcinoma","2025-08-18",{"date":161,"type":37},"2025-08-19",{"date":163,"type":37},"2025-04-30",{"date":165,"type":21},"2028-12",{"name":43,"class":44},""]